Compare EPAM Systems Inc (EPAM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Neurocrine Biosciences Inc — how do they compare? EPAM Systems Inc trades at $99.3 (market cap $5.15B), while Neurocrine Biosciences Inc trades at $154.01 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.2× EPAM Systems Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| EPAM | NBIX | |
|---|---|---|
Market Cap | $5.15B | $16.46B |
Sector | Technology | Health |
52-Week High | $221.40 | $185.50 |
52-Week Low | $76.04 | $123.10 |
Enterprise Value | $4.52B | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
